Volume 24, Issue 1 (4-2022)                   yafte 2022, 24(1): 84-98 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbaszadeh A, Torkzaban F, Morad Khani M R, Farhadi S, Hasanvand A. Co-administration of Epalrestat and Sitagliptin attenuate development and existing pain in a rat model of neuropathic pain: Role of anti-inflammatory and antioxidative effects. yafte. 2022; 24 (1) :84-98
URL: http://yafte.lums.ac.ir/article-1-3495-en.html
lorestan university of medical science
Abstract:   (309 Views)
Background: Neuropathic pain is one of the most important consequences of nerve damage, manifesting itself as various demonstrations, including hyperalgesia and allodynia. The present study aimed to investigate the effect of concomitant use of Epalrestat and Sitagliptin on pain reduction in the chronic constriction injury (CCI) model in rats through anti-inflammatory and antioxidant effects.
Materials and Methods: The present study was conducted on a total of 50 male rats that were randomly assigned to five groups: sham, CCI, CCI+Epalrestat(100 mg/kg, IP injection, for 14 days), CCI+Sitagliptin(10 mg/kg, IP injection, for 14 days), and CCI+Epalrestat(100 mg/kg)+Sitagliptin(10 mg/kg). Rats underwent behavioral tests on days 4, 7, and 14 after the surgery. After 14 days, the spinal cord was collected to measure anti-inflammatory and antioxidant tissue concentrations.
Results: The results of this study demonstrated that simultaneous injection of these two drugs in group 5 had the most neuroprotective effect, compared to that in groups 3 and 4. The results of dynamic responses to mechanical stimulation on the 14th day illustrated that there was no significant difference in groups 3 and 4 . Nonetheless, in Group 5, a significant difference was detected in all factors. The results pointed out that the combined use of Epalrestat and Sitagliptin decreased the levels of Tumor necrosis factor, Interleukin 6, and MDA, and also increased the level of glutathione peroxidase
Conclusion: As evidenced by the obtained results, the concomitant use of Epalrestat and Sitagliptin can be considered effective and safe for the treatment of neuropathic pain with strong inhibition of inflammatory factors and oxidative stress.
Full-Text [PDF 493 kb]   (159 Downloads)    
Type of Study: Research | Subject: فارماکولوژی
Received: 2022/03/7 | Accepted: 2022/04/30 | Published: 2022/04/30

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Yafteh

Designed & Developed by : Yektaweb